tiprankstipranks
Advertisement
Advertisement

IMRX Stock Latest News

Immuneering publishes preclinical data on atebimetinib in Cancer Research
The FlyImmuneering publishes preclinical data on atebimetinib in Cancer Research
2h ago
IMRX
Immuneering initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Immuneering initiated with an Overweight at Cantor Fitzgerald
13d ago
IMRX
Immuneering Appoints Veteran Biotech Leader as New CFO
PremiumCompany Announcements
Immuneering Appoints Veteran Biotech Leader as New CFO
1M ago
8K
IMRX
Immuneering appoints Andrew Gengos as CFO
PremiumThe Fly
Immuneering appoints Andrew Gengos as CFO
1M ago
IMRX
Immuneering Shareholders Approve Directors and Auditor at Meeting
PremiumCompany Announcements
Immuneering Shareholders Approve Directors and Auditor at Meeting
1M ago
8K
IMRX
Immuneering Buy Rating Reaffirmed as Analyst Sees ASCO Sell-Off as Overdone; $11 Price Target Maintained
PremiumRatingsImmuneering Buy Rating Reaffirmed as Analyst Sees ASCO Sell-Off as Overdone; $11 Price Target Maintained
2M ago
IMRX
Immuneering Advances Atebimetinib With Positive Phase 2a Results
Premium
Company Announcements
Immuneering Advances Atebimetinib With Positive Phase 2a Results
2M ago
8K
IMRX
Midday Fly By: Nvidia unveils new PC chip, Berkshire to buy Taylor Morrison
Premium
The Fly
Midday Fly By: Nvidia unveils new PC chip, Berkshire to buy Taylor Morrison
2M ago
GM
AMC
Immuneering announces updated clinical data from atebimetinib combination trial
PremiumThe Fly
Immuneering announces updated clinical data from atebimetinib combination trial
2M ago
IMRX
Immuneering reports Q1 EPS (21c), consensus (25c)
PremiumThe Fly
Immuneering reports Q1 EPS (21c), consensus (25c)
2M ago
IMRX
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
PremiumCompany Announcements
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
3M ago
IMRX
Immuneering announces updated data from Phase 2a trial for atebimetinib
PremiumThe Fly
Immuneering announces updated data from Phase 2a trial for atebimetinib
3M ago
IMRX
Immuneering announces presentation of new genetic data at 2026 AACR
PremiumThe FlyImmuneering announces presentation of new genetic data at 2026 AACR
3M ago
IMRX
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
3M ago
ANGX
IMRX
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
4M ago
EVAX
IMRX
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
4M ago
MWH
AKTS
Immuneering price target lowered to $12 from $13 at Piper Sandler
PremiumThe Fly
Immuneering price target lowered to $12 from $13 at Piper Sandler
4M ago
IMRX
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
PremiumRatings
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
4M ago
IMRX
Midday Fly By: Rising oil prices, falling employment sink stocks
PremiumThe Fly
Midday Fly By: Rising oil prices, falling employment sink stocks
5M ago
BA
BX
Immuneering reports Q4 EPS (18), consensus (31c)
PremiumThe FlyImmuneering reports Q4 EPS (18), consensus (31c)
5M ago
IMRX
Immuneering sees cash runway into 2029
Premium
The Fly
Immuneering sees cash runway into 2029
5M ago
IMRX
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
Premium
The Fly
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
6M ago
IMRX
RVMD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >